Valsartan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Valsartan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
467
Registered trials
100
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Valsartan can convert its Small molecule drug profile and AT1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Valsartan (query alias: valsartan) |
|---|---|
| Modality / target | Small molecule drug; AT1R; AT1R antagonists |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Novartis Pharmaceuticals Australia Pty Ltd., Novartis Pharmaceuticals Corp., Novartis Pharma KK |
The MCP disease footprint includes Myocardial Infarction, Heart Failure, Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-UMIN000061780 | Phase 4 | 開始前/Preinitiation | 140 | 最終評価時（12週時）の診察室目標血圧達成率 |
| NCT07547878 | Phase 4 | Not yet recruiting | 64 | On-study retention rate at 6 months |
| NCT07539298 | Phase 2/3 | Not yet recruiting | 50 | Mitral leaflet size |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
Phase 3; n=1112; evaluation: not stated. Reported fields: Total eGFR Slope (Coprimary Analysis #1)(Least Squares Mean) = -4.5622 mL/min/(1.73 m2)/yr (95% Confidence Interval, -5.9969 to -3.1275); Total eGFR Slope (Coprimary Analysis #1)(Least Squares Mean): Treatment difference in mean slope = -0.7354(95% CI, -2.7311 to 1.2604), P-Value = 0.4691; Total eGFR Slope (Coprimary Analysis #1)(Least Squares Mean) = -5.2975 mL/min/(1.73 m2)/yr (95% Confidence Interval, -6.6854 to -3.9097)
Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients
Phase 3; n=13903; evaluation: Positive. Reported fields: ESKD(at SBP 130-139 mmHg): HR = 0.442(95.0% CI, 0.196 - 1.0), P-Value = 0.05; ESKD(at SBP 130-139 mmHg): HR = 0.442(95.0% CI, 0.196 - 1.0), P-Value = 0.05
Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial
Phase 2; n=60; evaluation: Positive. Reported fields: HbA1c: P-Value = 0.007; HbA1c: P-Value = 0.007
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Valsartan addresses Myocardial Infarction, Heart Failure, Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2017-10-31 | Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences | Approved | US$0.1M upfront; US$0.4M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Valsartan-levoamlodipine tablet composition, valsartan-levoamlodipine tablet as well as preparation process and application of valsartan-levoamlodipine tablet”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of valsartan”. The milestone feed surfaced a patent-application signal described as “Method for detecting active ingredients and impurities in valsartan-levoamlodipine tablet”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
